Filing Details
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:KPTI
Karyopharm Therapeutics Inc. (KPTI) Files Quarterly Report for Q0
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
At publication ·
What changed
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed its quarterly report (Form 10-Q) on August 13, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $1.99 with a market capitalization of $59.5 million as of the filing date.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last annual filing.
Market Context
Karyopharm Therapeutics Inc.'s stock currently trades at $1.99 with a market capitalization of $59.5M.
The 10-Q provides Karyopharm Therapeutics Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Karyopharm Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KPTI Stock Page
Frequently Asked Questions
Where can I read KPTI's SEC filings?
Browse all filings on our KPTI SEC filings page.
What types of SEC filings does Karyopharm Therapeutics Inc. file?
Public companies like Karyopharm Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.